Targeted Strategies for Today's Evolving Markets

MissionIR Blog

BioScrip Inc. (BIOS) Receives “Buy” Rating; 10% Revenue Growth Expected

BioScrip Inc. (Nasdaq: BIOS) is a pharmaceutical healthcare organization that provides medications and management solutions for pharmacies and other related healthcare venues in the United States. The company operates through its Specialty Services and PBM Services segments. As of December 31, 2007, BioScrip operated 40 pharmacies in the United States, including community, mail and infusion pharmacies.

The company recently received a “Buy” rating from Noble Financial, with a price target of $6.50. The firm expects 9.5-10 percent revenue growth, as well as more than 50 percent earnings per share growth over the next three years. BioScrip can achieve this through the likely “significant capture of efficiencies.”

The specialty pharmacy industry is a rapidly growing market, enhanced by its convenient location features across metropolitan areas. For health, transportation or other issues, patients are finding mail delivered prescriptions a quick, cost-effective way to obtain prescriptions.

BioScrip offers both of these services, as well as the ability to order prescriptions, check prescription status and track prescription history through the BioScrip Web site. The company is partnered with healthcare payors, pharmaceutical manufacturers, government agencies, physicians and patients to provide medications and programs to its consumers.

Community pharmacy locations are scattered throughout metropolitan markets, allowing patients to fulfill their pharmacy needs close to home. Pharmacy Benefit Management (PBM) Services include benefit plan design, pharmacy network management, mail service, sophisticated data management and reporting services. BioScrips Specialty Mail Services include free nationwide delivery of specialty medications, clinical services, therapy management and Web-based reporting. Finally, the company’s In-clinic and In-home Infusion Therapy Services provide intravenous medications and fluids that can be administered in the comfort of the patient’s home or at their physician’s office.

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *